DA Davidson analyst William Jellison keeps a Buy rating and $36 price target on Phreesia (PHR) while naming the company the firm’s 2025 top pick in Vertical Software. The stock remains “poorly understood” by the market and believed to be a healthcare company, whereas it clearly adheres to a business model and exhibits characteristics most closely aligned with Vertical Software, the analyst tells investors in a research note. Phreesia also has no debt, likely about $50M of free cash flow in 2025, and 2025 revenue growth of 14%, which is third quartile versus 19 other Vertical Software peers, the firm sates, adding that shares trade at enterprise value of just 20x EBITDA vs. a Vertical peer median multiple of 32x.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PHR:
- Phreesia price target raised to $34 from $31 at Truist
- Phreesia price target lowered to $30 from $34 at Baird
- Phreesia’s Global Expansion: Navigating Legal Hurdles and Compliance Costs
- Phreesia Reports Strong Q3 2025 Performance
- Phreesia jumps 6% to $22.83 after Q3 results, updated guidance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
